Literature DB >> 18000061

Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis.

Georgios T Stathopoulos1, Taylor P Sherrill, Dong-Sheng Cheng, Robert M Scoggins, Wei Han, Vasiliy V Polosukhin, Linda Connelly, Fiona E Yull, Barbara Fingleton, Timothy S Blackwell.   

Abstract

Chronic inflammation is linked to carcinogenesis in several organ systems. In the lungs, NF-kappaB, a central effector of inflammatory responses, is frequently activated in non-small-cell lung cancer, but its role in tumor promotion has not been studied. Several lines of evidence indicate that ethyl carbamate (urethane)-induced lung tumor formation, a prototypical mouse model of multistage lung carcinogenesis, is potentiated by inflammation. We found that mouse strains susceptible to lung tumor formation (FVB, BALB/c) exhibited early NF-kappaB activation and inflammation in the lungs after urethane treatment. However, a resistant strain (C57B6) failed to activate NF-kappaB or induce lung inflammation. In FVB mice, we identified urethane-induced NF-kappaB activation in airway epithelium, as well as type II alveolar epithelial cells and macrophages. Using an inducible transgenic mouse model (FVB strain) to express a dominant inhibitor of NF-kappaB specifically in airway epithelial cells, we found that urethane-induced lung inflammation was blocked and tumor formation was reduced by >50%. Selective NF-kappaB inhibition resulted in increased apoptosis of airway epithelial cells at 2 weeks after urethane treatment in association with a marked reduction of Bcl-2 expression. These studies indicate that NF-kappaB signaling in airway epithelium is integral to tumorigenesis in the urethane model and identify the NF-kappaB pathway as a potential target for chemoprevention of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000061      PMCID: PMC2141808          DOI: 10.1073/pnas.0705316104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Airways obstruction and the risk for lung cancer.

Authors:  M S Tockman; N R Anthonisen; E C Wright; M G Donithan
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex.

Authors:  R J Fijneman; L C Oomen; M Snoek; P Demant
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Pulmonary adenoma susceptibility 1 (Pas1) locus affects inflammatory response.

Authors:  Durvanei Augusto Maria; Giacomo Manenti; Federica Galbiati; Orlando Garcia Ribeiro; Wafa Hanna Koury Cabrera; Roberto Giannì Barrera; Angela Pettinicchio; Marcelo De Franco; Nancy Starobinas; Maria Siqueira; Tommaso A Dragani; Olga Martinez Ibañez
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

Review 6.  10 years of mouse cancer modifier loci: human relevance.

Authors:  Tommaso A Dragani
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

Review 7.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

8.  Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  L H Kuller; J Ockene; E Meilahn; K H Svendsen
Journal:  Am J Epidemiol       Date:  1990-08       Impact factor: 4.897

9.  Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study.

Authors:  D M Skillrud; K P Offord; R D Miller
Journal:  Ann Intern Med       Date:  1986-10       Impact factor: 25.391

10.  Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency.

Authors:  Heike Bernert; Kenji Sekikawa; Richard A Radcliffe; Fuad Iraqi; Ming You; Alvin M Malkinson
Journal:  Mol Carcinog       Date:  2003-11       Impact factor: 4.784

View more
  91 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.

Authors:  Sophia P Karabela; Ioannis Psallidas; Taylor P Sherrill; Chrysoula A Kairi; Rinat Zaynagetdinov; Dong-Sheng Cheng; Spyridoula Vassiliou; Frank McMahon; Linda A Gleaves; Wei Han; Ioannis Stathopoulos; Spyros G Zakynthinos; Fiona E Yull; Charis Roussos; Ioannis Kalomenidis; Timothy S Blackwell; Georgios T Stathopoulos
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

3.  Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis.

Authors:  Cesar E Ochoa; Seyedeh Golsar Mirabolfathinejad; Venado Ana Ruiz; Scott E Evans; Mihai Gagea; Christopher M Evans; Burton F Dickey; Seyed Javad Moghaddam
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-22

4.  Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis.

Authors:  Ioanna Giopanou; Ioannis Lilis; Vassilios Papaleonidopoulos; Theodora Agalioti; Nikolaos I Kanellakis; Nikolitsa Spiropoulou; Magda Spella; Georgios T Stathopoulos
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

5.  Myeloid-derived suppressor cells in the development of lung cancer.

Authors:  Myrna L Ortiz; Lily Lu; Indu Ramachandran; Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2013-10-18       Impact factor: 11.151

Review 6.  Luteolin, a flavonoid with potential for cancer prevention and therapy.

Authors:  Yong Lin; Ranxin Shi; Xia Wang; Han-Ming Shen
Journal:  Curr Cancer Drug Targets       Date:  2008-11       Impact factor: 3.428

7.  Nrf2-activated expression of sulfiredoxin contributes to urethane-induced lung tumorigenesis.

Authors:  Murli Mishra; Hong Jiang; Hedy A Chawsheen; Matthieu Gerard; Michel B Toledano; Qiou Wei
Journal:  Cancer Lett       Date:  2018-06-15       Impact factor: 8.679

8.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

9.  Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.

Authors:  Natália R Salinas; Camila T Lopes; Patrícia V Palma; Celina T Oshima; Valquiria Bueno
Journal:  Pathol Oncol Res       Date:  2009-02-12       Impact factor: 3.201

10.  Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner.

Authors:  Elizabeth A Rondini; Dianne M Walters; Alison K Bauer
Journal:  Part Fibre Toxicol       Date:  2010-04-12       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.